Hy Labs (Hy Laboratories Ltd) is a leading diagnostic company in Israel, specializing in microbiology, particularly in infection diseases. With a history spanning five decades, the company is focused on developing, producing, and marketing services and products for the detection and identification of microorganisms. Embracing advanced molecular methods such as RTPCR and NGS (Next Generation Sequencing), Hy Labs caters to clinical, industrial, research, and innovation markets, alongside producing classical tools for conventional culturing methods. The company's products and services are designed to meet the highest international and local standards, supported by extensive knowledge and proficiency of its staff. Hy Labs' R&D team collaborates with leading experts in the microbiology and molecular biology fields, striving to make the world's most advanced technologies accessible to the market. Boasting an internal quality assurance unit to ensure accuracy and reliability, the company also operates professional customer service and support teams, providing technical assistance on-site and remotely. Founded in 1974 and headquartered in Israel, Hy Labs operates in the Biotechnology, Health Care, and Manufacturing industries. Currently, there is no publicly disclosed information about the company's last investment or the involved investors. Overall, Hy Labs stands out for its long-standing expertise in microbiology, commitment to technological advancement, and dedication to high-quality customer service, making it a noteworthy player in the field of diagnostic tools for microorganisms and molecular biology.
There is no investment information
No recent news or press coverage available for hylabs (Hy Laboratories Ltd).